AMED - Amedisys, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
136.22
-2.51 (-1.81%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close138.73
Open136.10
Bid136.00 x 900
Ask136.85 x 900
Day's Range134.49 - 136.76
52 Week Range55.49 - 140.91
Volume698,499
Avg. Volume409,633
Market Cap4.344B
Beta (3Y Monthly)1.62
PE Ratio (TTM)52.84
EPS (TTM)2.58
Earnings DateFeb 27, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est126.64
Trade prices are not sourced from all markets
  • Benzinga3 days ago

    Cannabis REIT Innovative Industrial Properties Joins Small-Cap Index

    The cannabis industry reached another investment milestone when Standards & Poors announced Thursday that it will add the cannabis REIT Innovative Industrial Properties (NYSE: IIPR) to its 600 SmallCap Index next week. IIP is an industry leader in providing real estate capital for the medical cannabis sector. Its addition to the SmallCap Index comes as previous member Amedisys Inc (NASDAQ: AMED) moves up to the MidCap 400 Index.

  • Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
    Zacks3 days ago

    Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

    Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

  • PR Newswire4 days ago

    Amedisys Set to Join S&P MidCap 400; Innovative Industrial Properties to Join S&P SmallCap 600

    NEW YORK , Feb. 14, 2019 /PRNewswire/ -- S&P SmallCap 600 constituent Amedisys Inc. (NASD: AMED) will replace Aspen Insurance Holdings Ltd. (NYSE: AHL) in the S&P MidCap 400, and Innovative Industrial ...

  • GlobeNewswire5 days ago

    Media Statement from Amedisys Commending the Home Health Payment Innovation Act

    Amedisys, Inc. (AMED), America’s leading independent home health, hospice and personal care company, commends bipartisan legislation to preserve and expand home health to those who need it the most. “Monday, our congressional champions introduced S. 433 – The Home Health Payment Innovation Act, once again showing support for home health and the value it provides to Medicare beneficiaries,” stated Amedisys President and CEO Paul Kusserow. The bipartisan bill, introduced in Congress on Monday night, would not only preserve but also expand access for millions of Medicare beneficiaries to vitally needed health care services that are delivered to the home.

  • Boston Scientific Benefits From New Buyouts & Product Launch
    Zacks5 days ago

    Boston Scientific Benefits From New Buyouts & Product Launch

    Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.

  • Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
    Zacks5 days ago

    Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

    The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.

  • Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
    Zacks6 days ago

    Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

    IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Amedisys Inc.

    Amedisys Inc NASDAQ/NGS:AMEDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AMED with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AMED totaled $349 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Amedisys (AMED) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks11 days ago

    Amedisys (AMED) Upgraded to Buy: What Does It Mean for the Stock?

    Amedisys (AMED) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire12 days ago

    Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date

    Amedisys, Inc. (AMED), announced today that it will report results for the fourth quarter and year ended December 31, 2018, after the market closes on February 27, 2019. The Company will host an investor conference call to discuss these results at 10:00 a.m. ET on February 28, 2019. To participate on the conference call, please call a few minutes before 10:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll).

  • 3 Investment Tips to Help You Achieve Your 2019 Goals
    Zacks12 days ago

    3 Investment Tips to Help You Achieve Your 2019 Goals

    Here are a few ways to invest your money that will help you improve your financial health and mitigate the impacts of any potential adversity.

  • What Does Amedisys, Inc.’s (NASDAQ:AMED) P/E Ratio Tell You?
    Simply Wall St.13 days ago

    What Does Amedisys, Inc.’s (NASDAQ:AMED) P/E Ratio Tell You?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! This article is for investors who would Read More...

  • GlobeNewswire14 days ago

    Amedisys Closes on Acquisition of Compassionate Care Hospice

    Amedisys, Inc. (the “Company” or “Amedisys”) (AMED), America’s leading independent home health, hospice and personal care company, has closed on its acquisition of Compassionate Care Hospice, a hospice provider headquartered in Parsippany, New Jersey, with 2,300 employees and 53 locations nationwide. Under the terms of the agreement, Amedisys acquired 100 percent of the ownership interests in Compassionate Care Hospice for a fixed price of $340 million, which is inclusive of $50 million in payments related to a tax asset and working capital.

  • Amedisys (AMED) Gains But Lags Market: What You Should Know
    Zacks19 days ago

    Amedisys (AMED) Gains But Lags Market: What You Should Know

    Amedisys (AMED) closed the most recent trading day at $129.41, moving +1.47% from the previous trading session.

  • Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark
    Zacks19 days ago

    Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark

    Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.

  • Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
    Zacks19 days ago

    Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

    Is (AMED) Outperforming Other Medical Stocks This Year?

  • ADUS vs. AMED: Which Stock Should Value Investors Buy Now?
    Zacks19 days ago

    ADUS vs. AMED: Which Stock Should Value Investors Buy Now?

    ADUS vs. AMED: Which Stock Is the Better Value Option?

  • Thermo Fisher (TMO) Down on Business Divestment Declaration
    Zacks20 days ago

    Thermo Fisher (TMO) Down on Business Divestment Declaration

    Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.

  • Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
    Zacks20 days ago

    Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

    We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.

  • Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
    Zacks24 days ago

    Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

    Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).

  • Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Shoe Carnival, Amedisys, Expeditors International of Washington and Stitch Fix
    Zacks25 days ago

    Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Shoe Carnival, Amedisys, Expeditors International of Washington and Stitch Fix

    Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Shoe Carnival, Amedisys, Expeditors International of Washington and Stitch Fix

  • Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)
    Zacks26 days ago

    Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)

    Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.